Physician profile
Stephen Michael Panosian
NPI 1093355430
$1,701.55
in general payments reported to CMS, 2019-2025
26 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $372 · 2023: $649 · 2024: $392 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $297.05 | 2021-2024 | |
| Lilly USA, LLC | $291.51 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $172.45 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Novo Nordisk INC | $170.34 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $104.53 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.48 | 2022-2023 | Jardiance |
| Tandem Diabetes Care, INC. | $63.49 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $62.80 | 2021-2023 | Senza |
| Novartis Pharmaceuticals Corporation | $61.32 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $45.26 | 2023 | |
| Glaxosmithkline, LLC. | $36.89 | 2023 | Trelegy Ellipta, Arexvy |
| Eisai INC. | $31.73 | 2024 | |
| Xeris Pharmaceuticals, INC. | $27.79 | 2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals Lp | $27.41 | 2023 | Airsupra, Breztri |
| Insulet Corporation | $27.35 | 2024-2025 | Omnipod |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.87 | 2021 | |
| Amgen INC. | $23.20 | 2022 | |
| Mannkind Corporation | $21.86 | 2023 | Afrezza |
| Impulse Dynamics (USA) INC. | $17.47 | 2023 | Optimizer |
| Pfizer INC. | $17.39 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.24 | 2024 | |
| Inspire Medical Systems, INC. | $15.09 | 2025 | Inspire |
| Cranial Technologies, INC | $15.04 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.88 | 2025 | Spravato |
| Bardy Diagnostics, INC. | $14.30 | 2022 | |
| Sanofi Pasteur INC. | $13.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Panosian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.